• LAST PRICE
    14.3520
  • TODAY'S CHANGE (%)
    Trending Up0.0720 (0.5042%)
  • Bid / Lots
    14.3400/ 7
  • Ask / Lots
    14.3800/ 4
  • Open / Previous Close
    14.3900 / 14.2800
  • Day Range
    Low 14.0100
    High 14.4950
  • 52 Week Range
    Low 12.9500
    High 25.4700
  • Volume
    304,881
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jul 9, 2024

      Show headlines and story abstract
    • 4:35PM ET on Tuesday Jul 09, 2024 by Business Wire
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 25,200 shares of the Company's common stock at an exercise price per share of $13.84, which was the closing price on July 8, 2024, and restricted stock units to acquire a total of 12,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

    • 4:35PM ET on Tuesday Jul 09, 2024 by Dow Jones
      Companies Mentioned: RCUS
      HAYWARD, Calif.--(BUSINESS WIRE)--July 09, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 25,200 shares of the Company's common stock at an exercise price per share of $13.84, which was the closing price on July 8, 2024, and restricted stock units to acquire a total of 12,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
    • 4:05AM ET on Tuesday Jul 09, 2024 by MT Newswires
      Companies Mentioned: RCUS
      04:05 AM EDT, 07/09/2024 (MT Newswires) -- Arcus Biosciences (RCUS) said Monday that Taiho Pharmaceutical exercised its option for an exclusive license to quemliclustat, an investigational small molecule CD73 inhibitor, in Japan and some other terri...
  • Jul 8, 2024

Peers Headlines